Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.
Talb J, Takam Kamga P, Mayenga M, Costantini A, Julié C, Dumenil C, Dumoulin J, Ouaknine J, Giraud V, Dujon C, Azarian R, Glaser C, Emile JF, Giroux Leprieur E. Talb J, et al. Among authors: dujon c. Cancer Immunol Immunother. 2022 Nov;71(11):2791-2799. doi: 10.1007/s00262-022-03206-4. Epub 2022 Apr 18. Cancer Immunol Immunother. 2022. PMID: 35435450 Free PMC article.
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E. Mehlman C, et al. Among authors: dujon c. Lung Cancer. 2019 Nov;137:149-156. doi: 10.1016/j.lungcan.2019.09.019. Epub 2019 Sep 28. Lung Cancer. 2019. PMID: 31600593
[Spontaneous regression of a pulmonary adenocarcinoma].
Dujon C, Glaser C, Azarian R, Petitpretz P. Dujon C, et al. Rev Mal Respir. 2017 Jan;34(1):86-88. doi: 10.1016/j.rmr.2016.04.025. Epub 2016 Jun 3. Rev Mal Respir. 2017. PMID: 27266898 French. No abstract available.
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O. Delanoy N, et al. Among authors: dujon c. Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4. Lancet Haematol. 2019. PMID: 30528137
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Chouaid C, Le Caer H, Locher C, Dujon C, Thomas P, Auliac JB, Monnet I, Vergnenegre A; GFPC 0504 Team. Chouaid C, et al. Among authors: dujon c. BMC Cancer. 2012 Jul 20;12:301. doi: 10.1186/1471-2407-12-301. BMC Cancer. 2012. PMID: 22817667 Free PMC article. Clinical Trial.
A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer.
Lerouge D, Rivière A, Dansin E, Chouaid C, Dujon C, Schott R, Lavole A, Le Pennec V, Fabre E, Crequit J, Martin F, Dehette S, Fournel P, Precheur-Agulhon B, Lartigau E, Zalcman G. Lerouge D, et al. Among authors: dujon c. BMC Cancer. 2014 Mar 30;14:231. doi: 10.1186/1471-2407-14-231. BMC Cancer. 2014. PMID: 24678902 Free PMC article. Clinical Trial.
25 results